Resolution of Thrombi in Left Atrial Appendage With Edoxaban

Inclusion Criteria: * Men or women aged ≥ 20 years * Hemodynamically stable nonvalvular AF or atrial flutter * LAA thrombus documented by TEE up to 72 hours prior to start of study medication * VKA or NOAC-naïve or untreated within 1 month prior to sign the informed consent * VKA pretreated but under the therapeutic International Normalized ratio levels (\<2.0; documented with at least 2 consecutive measurements that are at least 24 hours apart) within last 6 weeks * Women of childbearing potential and men must agree to use adequate contraception when sexually active Exclusion Criteria: * Transient Ischemic Attack within 3 days prior to study inclusion * Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 months or any stroke within 14 days before the start of study drug * Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to study inclusion * Acute myocardial infarction within the last 14 days prior to study inclusion * Cardiac-related criteria: Previous intracardiac thrombus, Free-floating ball thrombus, Intracardiac tumor, known left ventricular or aortic thrombus * Active bleeding or high risk for bleeding contraindicating anticoagulant therapy